This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Post-Operative Nausea And Vomiting industry.
What is the projected value of the post-operative nausea and vomiting market by 2029?
The post-operative nausea and vomiting market size has grown strongly in recent years. It will grow from $2.11 billion in 2024 to $2.26 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to rising research and development activities, growing demand for advanced therapies, rise in healthcare expenditure, growing focus on personalized medicine, and increasing adoption of digital health technologies.
The post-operative nausea and vomiting market size is expected to see strong growth in the next few years. It will grow to $2.97 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to growing demand for pharmaceuticals, rise in combination therapy, rising awareness and healthcare investment, increased geriatric population, and rising number of cancer cases. Major trends in the forecast period include advanced antiemetic therapies, strategic collaboration, innovative drug formulations, integration of advanced diagnostic tools, and electronic simulation devices.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22109&type=smp
How are technological advancements fueling growth in the post-operative nausea and vomiting market?
The rising number of surgical procedures is expected to propel the growth of the post-operative nausea and vomiting market going forward. Surgical procedures are medical actions that use tools to find, treat, or remove damaged tissues, organs, or abnormalities by cutting or manipulating them. The number of surgical procedures are rising due to the advancements in medical technology, which have made surgeries safer, more effective, and minimally invasive contributing to patient acceptance and wider applicability. Post-operative nausea and vomiting management enhances surgical procedures by improving patient comfort, reducing recovery time, minimizing the risk of complications, ensuring smoother post-operative care, and ultimately enhancing overall surgical outcomes. For instance, in November 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in the 2023–24 period, 771,600 patients were admitted for surgery from public hospital elective surgery waiting lists, representing a 4.9% increase compared to 2022–23. Therefore, the rising number of surgical procedures is driving the growth of the post-operative nausea and vomiting market.
Which segment currently leads the post-operative nausea and vomiting market in terms of revenue share?
The post-operative nausea and vomiting market covered in this report is segmented –
1) By Treatment Type: Serotonin Antagonists, Steroids, Dopamine Antagonists, Neurokinin NK-1 Receptor Antagonists, Non-pharmacological Treatment, Other Treatment Types
2) By Route Of Administration: Oral, Intravenous, Transdermal, Other Route Of Administrations
3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients
4) By Surgical Procedure Type: Orthopedic Surgery, Gynecological Surgery, General Surgery, Cardiac Surgery, Ophthalmic Surgery
5) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users
Subsegmentss:
1) By Serotonin Antagonists Type: Ondansetron, Granisetron, Palonosetron, Dolasetron, Tropisetron
2) By Steroids Type: Dexamethasone, Methylprednisolone, Hydrocortisone, Prednisolone, Betamethasone
3) By Dopamine Antagonists Type: Metoclopramide, Droperidol, Prochlorperazine, Domperidone, Chlorpromazine
4) By Neurokinin NK-1 Receptor Antagonists Type: Aprepitant, Fosaprepitant, Rolapitant, Netupitant, Casopitant
5) By Non-Pharmacological Treatment Type: Acupressure, Aromatherapy, Hypnotherapy, Electroacupuncture, Ginger Supplements
6) By Other Treatment Types: Antihistamines, Anticholinergics, Cannabinoids, Combination Therapy, Herbal & Natural Remedies
View The Full Market Report:
What future trends will impact the direction of the post-operative nausea and vomiting industry?
Major companies operating in the post-operative nausea and vomiting market are focusing on developing critical injectable medications utilizing advanced emulsion formulations and sustained-release technology to improve efficacy and provide prolonged symptom relief for surgical patients. Critical injectable medications refer to essential drugs administered via injection that are designed to provide immediate and effective treatment for serious or urgent medical conditions. For instance, in July 2024, Avenacy, a US-based specialty pharmaceutical company, launched Palonosetron Hydrochloride Injection in 0.25 mg/5 mL single-dose vials to help healthcare providers reduce dosing errors and improve patient safety. This injection is indicated for preventing nausea and vomiting caused by chemotherapy and for managing postoperative nausea and vomiting (PONV) for up to 24 hours following surgery, offering a reliable treatment option for patients at risk of these conditions.
Who are the top competitors in the global post-operative nausea and vomiting market?
Major companies operating in the post-operative nausea and vomiting market are Pfizer Inc., Merck KGaA, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited. , Baxter Corporation, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Inc., Fresenius Kabi AG, Eisai Co. Ltd., Dr. Reddy’s Laboratories, Kyowa Hakko Kirin Taiwan Co. Ltd., Cipla Ltd., Alkem Laboratories Ltd., Eagle Pharmaceuticals Inc. , Camurus AB, Helsinn Healthcare SA, Heron Therapeutics Inc., Advacare Pharma
What regional dynamics are shaping the future of the global post-operative nausea and vomiting market?
North America was the largest region in the post-operative nausea and vomiting market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-operative nausea and vomiting market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Post-Operative Nausea And Vomiting Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22109
Need Customized Data On Post-Operative Nausea And Vomiting Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=22109&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
